Novo Nordisk stock fell as much as 10% Monday after it said its next-generation weight loss drug didn't meet its primary target.

Novo Nordisk stock fell as much as 10% Monday after it said its next-generation weight loss drug didn't meet its primary target.

Seduta pesante per la multinazionale danese del farmaco Novo Nordisk dopo aver reso pubblici dati deludenti sulla sperimentazione della terapia antiobesità Cagrisema. (ANSA)